Tehran University of Medical Sciences

Science Communicator Platform

Faculty Members have conducted research related to the Longitudinal Effects of Dimethyl Fumarate on Patient-Reported Outcome Measures in Multiple Sclerosis: Treatment Satisfaction, Quality of Life, Depressive Symptoms, Sleep, and Work Productivity
Roya Abolfazli
Roya Abolfazli

Associate Professor of Neurology

Department Neurology

School of Medicine

Amir Alam Hospital

Tehran University of Medical Sciences

All Documents
1. Longitudinal Effects of Dimethyl Fumarate on Patient-Reported Outcome Measures in Multiple Sclerosis: Treatment Satisfaction, Quality of Life, Depressive Symptoms, Sleep, and Work Productivity, Journal of Clinical Neuroscience (2026)
2. Longitudinal Effects of Dimethyl Fumarate on Patient-Reported Outcome Measures in Multiple Sclerosis: Treatment Satisfaction, Quality of Life, Depressive Symptoms, Sleep, and Work Productivity, Journal of Clinical Neuroscience (2026)
3. Efficacy and Safety of Peginterferon Beta-1A Compared to Interferon Beta-1A in Relapsing Remitting Multiple Sclerosis Patients: A Phase 3, Randomized, Non-Inferiority Clinical Trial (Pegintegrity), Multiple Sclerosis and Related Disorders (2024)
4. Efficacy and Safety of Peginterferon Beta-1A Compared to Interferon Beta-1A in Relapsing Remitting Multiple Sclerosis Patients: A Phase 3, Randomized, Non-Inferiority Clinical Trial (Pegintegrity), Multiple Sclerosis and Related Disorders (2024)
5. Evaluating Efficacy and Safety of Ocrelizumab Biosimilar (Xacrel) Compared to the Originator (Ocrevus) in Relapsing Multiple Sclerosis: A Phase Iii, Randomized, Equivalency, Clinical Trial, Scientific Reports (2024)
6. Evaluating Efficacy and Safety of Ocrelizumab Biosimilar (Xacrel) Compared to the Originator (Ocrevus) in Relapsing Multiple Sclerosis: A Phase Iii, Randomized, Equivalency, Clinical Trial, Scientific Reports (2024)
7. The Patient-Reported Outcomes for the New Brand-Generic Teriflunomide in Relapsing-Remitting Multiple Sclerosis, Clinical Neurology and Neurosurgery (2024)
8. Adverse Drug Reactions of Multiple Sclerosis Diseasemodifying Drugs, Basic and Clinical Neuroscience (2023)
9. Safety and Discontinuation Rate of Dimethyl Fumarate (Zadiva®) in Patients With Multiple Sclerosis: An Observational Retrospective Study, Journal of Clinical Medicine (2023)
10. Prevalence of Sexual Dysfunction and Related Risk Factors in Men With Multiple Sclerosis in Iran: A Multicenter Study, Neurology and Therapy (2021)
11. Prevalence of Sexual Dysfunction and Related Risk Factors in Men With Multiple Sclerosis in Iran: A Multicenter Study, Neurology and Therapy (2021)
12. Increased Level of Caspase-1 in the Serum of Relapsing-Remitting Multiple Sclerosis (Rrms) Patients, Iranian Journal of Allergy# Asthma and Immunology (2020)
13. A Comparison Study of Efficacy and Safety of a Biosimilar Form of Intramuscular Βeta-Interferon I-A Versus the Reference Product: A Randomized Controlled Clinical Trial in Iran, Iranian Journal of Pharmaceutical Research (2019)
14. Primary Progressive Multiple Sclerosis in Iran: A Consensus Recommendation for Diagnosis and Management, Multiple Sclerosis and Related Disorders (2018)
15. Primary Progressive Multiple Sclerosis in Iran: A Consensus Recommendation for Diagnosis and Management, Multiple Sclerosis and Related Disorders (2018)
16. Tolerability and Safety Profile of a New Brand-Generic Product of Glatiramer Acetate in Iranian Patients With Relapsing-Remitting Multiple Sclerosis: An Observational Cohort Study, Current Therapeutic Research - Clinical and Experimental (2018)
17. Diagnosis and Management of Neuromyelitis Optica Spectrum Disorder (Nmosd) in Iran: A Consensus Guideline and Recommendations, Multiple Sclerosis and Related Disorders (2017)
18. Diagnosis and Management of Neuromyelitis Optica Spectrum Disorder (Nmosd) in Iran: A Consensus Guideline and Recommendations, Multiple Sclerosis and Related Disorders (2017)
19. Trends of Quality of Life Changes in Amyotrophic Lateral Sclerosis Patients, Journal of the Neurological Sciences (2016)
20. Amyotrophic Lateral Sclerosis Progression: Iran-Als Clinical Registry, a Multicentre Study, Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration (2015)
21. Amyotrophic Lateral Sclerosis Progression: Iran-Als Clinical Registry, a Multicentre Study, Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration (2015)
22. Hla-Drb1 Does Not Have a Role in Clinical Response to Interferon-Beta Among Iranian Multiple Sclerosis Patients, Journal of the Neurological Sciences (2015)
23. Interaural Difference Values of Vestibular Evoked Myogenic Potential in Migraine Patients, Acta Medica Iranica (2015)